ARTICLE | Emerging Company Profile
Taysha: Applying AAV9 across the CNS
Taysha is leveraging the experience of former AveXis executives to develop AAV9 gene therapies
April 29, 2020 12:01 PM UTC
Updated on Apr 29, 2020 at 4:46 PM UTC
Taysha launched with a $30 million seed round and a team of former AveXis leaders ready to parlay their experience with Zolgensma into a broad pipeline of AAV9-based gene therapies for other CNS disorders.
The company spun out of the University of Texas Southwestern Medical Center with a pipeline of 15 gene therapy programs, an option to four more and an ongoing partnership with UT Southwestern...
BCIQ Company Profiles